[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fvnCfensa7fBteWcAxXhDojm-53cDJ-gm34CnLvdcea0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":39,"rows":46},"Norgine",[4],54,false,1,14,22974,2,3,[14,17,19,21,24,27,29,31],{"name":15,"count":16},"Fecal Incontinence",6,{"name":18,"count":16},"Colonoscopy",{"name":20,"count":16},"Colorectal Cancer",{"name":22,"count":23},"Hepatic Cirrhosis",5,{"name":25,"count":26},"Colon Cancer",4,{"name":28,"count":26},"Colon Cleansing",{"name":30,"count":26},"Chronic Constipation",{"name":32,"count":12},"Colorectal Carcinoma",[34],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT07218523","A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to \u003C 18 Years of Age in Preparation for Colonoscopy","2027-01-06","PLENVU®",[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,71,89,149,167,185,274,329,377,409,443,479,501,529,561,579,597,615,640,658,676,701,719,744,762,780,802,820,843,866,889,950,982,1004,1022,1047,1069,1087,1113,1131,1158,1176,1194,1212,1239,1257,1275,1293,1311,1329,1354],{"intervention":38,"totalTrials":8,"cells":48},{"EARLY_PHASE1":49,"PHASE1":52,"PHASE2":54,"PHASE3":56,"PHASE4":67,"NA":69},{"trials":50,"activeCount":51},[],0,{"trials":53,"activeCount":51},[],{"trials":55,"activeCount":51},[],{"trials":57,"activeCount":8,"soonestReadout":37},[58],{"nctId":35,"briefTitle":36,"status":59,"phases":60,"primaryCompletion":37,"completion":37,"start":61,"enrollment":62,"conditions":63,"interventions":65},"RECRUITING",[43],"2025-12-29",212,[64],"Bowel Cleansing Prior to Clinical Procedures",[38,66],"Sodium picosulfate",{"trials":68,"activeCount":51},[],{"trials":70,"activeCount":51},[],{"intervention":66,"totalTrials":8,"cells":72},{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":85,"NA":87},{"trials":74,"activeCount":51},[],{"trials":76,"activeCount":51},[],{"trials":78,"activeCount":51},[],{"trials":80,"activeCount":8,"soonestReadout":37},[81],{"nctId":35,"briefTitle":36,"status":59,"phases":82,"primaryCompletion":37,"completion":37,"start":61,"enrollment":62,"conditions":83,"interventions":84},[43],[64],[38,66],{"trials":86,"activeCount":51},[],{"trials":88,"activeCount":51},[],{"intervention":90,"totalTrials":26,"cells":91},"MOVIPREP",{"EARLY_PHASE1":92,"PHASE1":94,"PHASE2":109,"PHASE3":121,"PHASE4":123,"NA":147},{"trials":93,"activeCount":51},[],{"trials":95,"activeCount":51},[96],{"nctId":97,"briefTitle":98,"status":99,"phases":100,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":106},"NCT01834742","Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects","COMPLETED",[41],"2011-09","2011-12","2011-04",161,[20],[107,107,107,108,107,107,107,107],"NER1006","Moviprep",{"trials":110,"activeCount":51},[111],{"nctId":112,"briefTitle":113,"status":99,"phases":114,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":120},"NCT01714466","Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy",[42],"2013-07","2014-01","2012-10",240,[25],[107,90],{"trials":122,"activeCount":51},[],{"trials":124,"activeCount":51},[125,136],{"nctId":126,"briefTitle":127,"status":99,"phases":128,"primaryCompletion":129,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":134},"NCT01689792","A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)",[44],"2013-01","2013-12","2011-11",398,[20],[90,135],"CitraFleet",{"nctId":137,"briefTitle":138,"status":99,"phases":139,"primaryCompletion":140,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":145},"NCT00605228","A Phase IV Study, of the Efficacy, Safety, and Acceptability of Moviprep® Versus Colopeg® in Colonoscopy Preparation",[44],"2007-12","2007-05",400,[144],"Gastrointestinal Diseases",[90,146],"COLOPEG",{"trials":148,"activeCount":51},[],{"intervention":135,"totalTrials":8,"cells":150},{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":157,"PHASE4":159,"NA":165},{"trials":152,"activeCount":51},[],{"trials":154,"activeCount":51},[],{"trials":156,"activeCount":51},[],{"trials":158,"activeCount":51},[],{"trials":160,"activeCount":51},[161],{"nctId":126,"briefTitle":127,"status":99,"phases":162,"primaryCompletion":129,"completion":130,"start":131,"enrollment":132,"conditions":163,"interventions":164},[44],[20],[90,135],{"trials":166,"activeCount":51},[],{"intervention":146,"totalTrials":8,"cells":168},{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":175,"PHASE4":177,"NA":183},{"trials":170,"activeCount":51},[],{"trials":172,"activeCount":51},[],{"trials":174,"activeCount":51},[],{"trials":176,"activeCount":51},[],{"trials":178,"activeCount":51},[179],{"nctId":137,"briefTitle":138,"status":99,"phases":180,"primaryCompletion":140,"completion":140,"start":141,"enrollment":142,"conditions":181,"interventions":182},[44],[144],[90,146],{"trials":184,"activeCount":51},[],{"intervention":186,"totalTrials":187,"cells":188},"NRL972",8,{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":227,"PHASE3":259,"PHASE4":270,"NA":272},{"trials":190,"activeCount":51},[],{"trials":192,"activeCount":51},[193,204,211,219],{"nctId":194,"briefTitle":195,"status":99,"phases":196,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":201,"interventions":203},"NCT00856752","Evaluation of the Pharmacokinetics of NRL972 Following Pre-Administration of Rifampicin and Cyclosporine",[41],"2006-07","2006-08","2006-06",12,[202],"Pharmacokinetics",[186,186,186],{"nctId":205,"briefTitle":206,"status":99,"phases":207,"primaryCompletion":198,"completion":208,"start":199,"enrollment":200,"conditions":209,"interventions":210},"NCT00857480","Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin",[41],"2006-10",[22],[186,186,186],{"nctId":212,"briefTitle":213,"status":99,"phases":214,"primaryCompletion":215,"start":216,"enrollment":118,"conditions":217,"interventions":218},"NCT00896597","Reproducibility of Child-Turcotte-Pugh (CTP) Rating and NRL972 Pharmacokinetics in Patients With Cirrhosis",[41],"2009-12","2009-04",[22],[186],{"nctId":220,"briefTitle":221,"status":99,"phases":222,"primaryCompletion":198,"start":223,"enrollment":224,"conditions":225,"interventions":226},"NCT00856713","Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers",[41],"2006-03",72,[22],[186,186,186,186,186,186],{"trials":228,"activeCount":51},[229,240,249],{"nctId":230,"briefTitle":231,"status":99,"phases":232,"primaryCompletion":233,"completion":131,"start":234,"enrollment":235,"conditions":236,"interventions":239},"NCT00794716","PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)",[42],"2010-03","2008-06",125,[237,238],"Non-Alcoholic Fatty Liver Disease","Nonalcoholic Steatohepatitis",[186],{"nctId":241,"briefTitle":242,"status":99,"phases":243,"primaryCompletion":244,"completion":244,"start":244,"enrollment":245,"conditions":246,"interventions":248},"NCT00915057","Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972.",[42],"2009-03",100,[247],"Hepatitis, Viral, Human",[186],{"nctId":250,"briefTitle":251,"status":99,"phases":252,"primaryCompletion":253,"completion":254,"start":255,"enrollment":256,"conditions":257,"interventions":258},"NCT00856869","Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers",[41,42],"2005-02","2005-04","2004-08",52,[22,238],[186,186,186,186,186,186,186],{"trials":260,"activeCount":51},[261],{"nctId":262,"briefTitle":263,"status":99,"phases":264,"primaryCompletion":265,"completion":265,"start":266,"enrollment":267,"conditions":268,"interventions":269},"NCT00794482","Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.",[43],"2009-06","2008-03",1200,[22],[186],{"trials":271,"activeCount":51},[],{"trials":273,"activeCount":51},[],{"intervention":275,"totalTrials":26,"cells":276},"macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate",{"EARLY_PHASE1":277,"PHASE1":279,"PHASE2":281,"PHASE3":302,"PHASE4":325,"NA":327},{"trials":278,"activeCount":51},[],{"trials":280,"activeCount":51},[],{"trials":282,"activeCount":51},[283,293],{"nctId":284,"briefTitle":285,"status":99,"phases":286,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":291},"NCT00312481","MOVIPREP® Versus PICOLAX® Pilot Study",[42],"2006-05","2005-07",65,[18],[275,292],"NA picosulfate magnesium citrate",{"nctId":294,"briefTitle":295,"status":99,"phases":296,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":301},"NCT00321230","Clinical Evaluation of a New Reduced Volume Bowel Preparation",[42],"2001-05","2001-01",30,[18],[275],{"trials":303,"activeCount":51},[304,314],{"nctId":305,"briefTitle":306,"status":99,"phases":307,"completion":308,"start":309,"enrollment":310,"conditions":311,"interventions":312},"NCT00322062","MOVIPREP® Versus NaP Pivotal Phase III Study",[43],"2003-03","2002-04",340,[18],[275,313],"Sodium Phosphate Solution",{"nctId":315,"briefTitle":316,"status":99,"phases":317,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":322},"NCT00389233","A Phase III Trial to Assess the Efficacy, Acceptability and Safety of Moviprep® Versus a 4L PEG+E Standard Solution",[43],"2002-12","2002-06",360,[18],[323,324],"Macrogol3350 NA sulphate NACl KCl ascorbic acid NA ascorbate","Macrogol3350 Na sulphate Na bicarbonate NaCl KCl",{"trials":326,"activeCount":51},[],{"trials":328,"activeCount":51},[],{"intervention":330,"totalTrials":26,"cells":331},"Polyethylene glycol 3350 Na bicarbonate NaCl KCl",{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":355,"PHASE4":373,"NA":375},{"trials":333,"activeCount":51},[],{"trials":335,"activeCount":51},[],{"trials":337,"activeCount":51},[338,349],{"nctId":339,"briefTitle":340,"status":99,"phases":341,"completion":309,"start":342,"enrollment":343,"conditions":344,"interventions":346},"NCT00403858","Movicol in Childhood Constipation (ProMotion Study)",[42],"2000-10",60,[345],"Feces, Impacted",[347,348],"Polyethylene glycol 3350 NA bicarbonate NaCl KCl","Lactulose",{"nctId":350,"briefTitle":340,"status":99,"phases":351,"completion":352,"start":342,"enrollment":343,"conditions":353,"interventions":354},"NCT00404040",[42],"2002-07",[30],[347,348],{"trials":356,"activeCount":51},[357,366],{"nctId":358,"briefTitle":359,"status":99,"phases":360,"completion":361,"start":362,"enrollment":363,"conditions":364,"interventions":365},"NCT00403897","An Open Single Centre Study To Assess Treatment of Chronic Constipation in Children",[43],"2003-01","2001-08",81,[30],[330],{"nctId":367,"briefTitle":368,"status":99,"phases":369,"completion":370,"start":309,"enrollment":343,"conditions":371,"interventions":372},"NCT00403819","Study to Examine the Efficacy and Safety of Movicol in the Treatment of Chronic Constipation in Children",[43],"2003-04",[30],[330],{"trials":374,"activeCount":51},[],{"trials":376,"activeCount":51},[],{"intervention":107,"totalTrials":12,"cells":378},{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":387,"PHASE3":393,"PHASE4":405,"NA":407},{"trials":380,"activeCount":51},[],{"trials":382,"activeCount":51},[383],{"nctId":97,"briefTitle":98,"status":99,"phases":384,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":385,"interventions":386},[41],[20],[107,107,107,108,107,107,107,107],{"trials":388,"activeCount":51},[389],{"nctId":112,"briefTitle":113,"status":99,"phases":390,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":391,"interventions":392},[42],[25],[107,90],{"trials":394,"activeCount":51},[395],{"nctId":396,"briefTitle":397,"status":99,"phases":398,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":402,"interventions":403},"NCT02254486","Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults",[43],"2015-06","2014-09",621,[25,32,28],[107,404],"Trisulfate solution",{"trials":406,"activeCount":51},[],{"trials":408,"activeCount":51},[],{"intervention":410,"totalTrials":11,"cells":411},"PEG 3350 plus electrolytes",{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":426,"PHASE3":428,"PHASE4":439,"NA":441},{"trials":413,"activeCount":51},[],{"trials":415,"activeCount":51},[416],{"nctId":417,"briefTitle":418,"status":99,"phases":419,"primaryCompletion":420,"start":421,"enrollment":422,"conditions":423,"interventions":424},"NCT00868985","Effects of Oral PEG 3350 on Electrolyte Balance",[41],"2008-08","2008-01",114,[30],[410,425],"PEG 3350 without electrolytes",{"trials":427,"activeCount":51},[],{"trials":429,"activeCount":51},[430],{"nctId":431,"briefTitle":432,"status":99,"phases":433,"primaryCompletion":101,"completion":102,"start":434,"enrollment":118,"conditions":435,"interventions":437},"NCT01251822","Comparator Study of PEG 3350 Versus Prucalopride in Females With Chronic Constipation",[43],"2010-11",[436],"Constipation",[410,438],"Prucalopride",{"trials":440,"activeCount":51},[],{"trials":442,"activeCount":51},[],{"intervention":444,"totalTrials":11,"cells":445},"Zegerid",{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":462,"PHASE3":464,"PHASE4":475,"NA":477},{"trials":447,"activeCount":51},[],{"trials":449,"activeCount":51},[450],{"nctId":451,"briefTitle":452,"status":99,"phases":453,"primaryCompletion":434,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":460},"NCT01710995","A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions",[41],"2011-02","2010-10",20,[458,459],"Acid Reflux","Gastro Oesophageal Reflux Disease",[444,461],"Losec",{"trials":463,"activeCount":51},[],{"trials":465,"activeCount":51},[466],{"nctId":467,"briefTitle":468,"status":99,"phases":469,"primaryCompletion":470,"completion":470,"start":103,"enrollment":471,"conditions":472,"interventions":474},"NCT01493089","Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease",[43],"2011-10",239,[473],"Gastroesophageal Reflux",[444,461],{"trials":476,"activeCount":51},[],{"trials":478,"activeCount":51},[],{"intervention":461,"totalTrials":11,"cells":480},{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":489,"PHASE3":491,"PHASE4":497,"NA":499},{"trials":482,"activeCount":51},[],{"trials":484,"activeCount":51},[485],{"nctId":451,"briefTitle":452,"status":99,"phases":486,"primaryCompletion":434,"completion":454,"start":455,"enrollment":456,"conditions":487,"interventions":488},[41],[458,459],[444,461],{"trials":490,"activeCount":51},[],{"trials":492,"activeCount":51},[493],{"nctId":467,"briefTitle":468,"status":99,"phases":494,"primaryCompletion":470,"completion":470,"start":103,"enrollment":471,"conditions":495,"interventions":496},[43],[473],[444,461],{"trials":498,"activeCount":51},[],{"trials":500,"activeCount":51},[],{"intervention":313,"totalTrials":11,"cells":502},{"EARLY_PHASE1":503,"PHASE1":505,"PHASE2":507,"PHASE3":509,"PHASE4":525,"NA":527},{"trials":504,"activeCount":51},[],{"trials":506,"activeCount":51},[],{"trials":508,"activeCount":51},[],{"trials":510,"activeCount":51},[511,515],{"nctId":305,"briefTitle":306,"status":99,"phases":512,"completion":308,"start":309,"enrollment":310,"conditions":513,"interventions":514},[43],[18],[275,313],{"nctId":516,"briefTitle":517,"status":99,"phases":518,"completion":519,"start":520,"enrollment":320,"conditions":521,"interventions":522},"NCT00427089","Comparison of 2L NRL994 With NaP Preparation in Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening",[43],"2005-05","2004-09",[18],[523,524],"Macrogol 3350 Na sulphate NaCl KCl Ascorbic Acid Na Ascorbate","Sodium Phosphate solution",{"trials":526,"activeCount":51},[],{"trials":528,"activeCount":51},[],{"intervention":530,"totalTrials":11,"cells":531},"TZP-101",{"EARLY_PHASE1":532,"PHASE1":534,"PHASE2":545,"PHASE3":547,"PHASE4":557,"NA":559},{"trials":533,"activeCount":51},[],{"trials":535,"activeCount":51},[536],{"nctId":537,"briefTitle":538,"status":99,"phases":539,"primaryCompletion":540,"completion":541,"start":540,"enrollment":16,"conditions":542,"interventions":544},"NCT01668199","A Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery and Pharmacokinetics of 14C TZP-101",[41],"2012-02","2012-03",[543],"Postoperative Ileus",[530],{"trials":546,"activeCount":51},[],{"trials":548,"activeCount":51},[549],{"nctId":550,"briefTitle":551,"status":99,"phases":552,"primaryCompletion":553,"completion":553,"start":540,"enrollment":554,"conditions":555,"interventions":556},"NCT01710982","Study to Evaluate the Safety of Post-Operative TZP-101 (IV Ulimorelin) After Partial Bowel Resection",[43],"2012-04",27,[543],[530],{"trials":558,"activeCount":51},[],{"trials":560,"activeCount":51},[],{"intervention":404,"totalTrials":8,"cells":562},{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":569,"PHASE4":575,"NA":577},{"trials":564,"activeCount":51},[],{"trials":566,"activeCount":51},[],{"trials":568,"activeCount":51},[],{"trials":570,"activeCount":51},[571],{"nctId":396,"briefTitle":397,"status":99,"phases":572,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":573,"interventions":574},[43],[25,32,28],[107,404],{"trials":576,"activeCount":51},[],{"trials":578,"activeCount":51},[],{"intervention":523,"totalTrials":8,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":587,"PHASE4":593,"NA":595},{"trials":582,"activeCount":51},[],{"trials":584,"activeCount":51},[],{"trials":586,"activeCount":51},[],{"trials":588,"activeCount":51},[589],{"nctId":516,"briefTitle":517,"status":99,"phases":590,"completion":519,"start":520,"enrollment":320,"conditions":591,"interventions":592},[43],[18],[523,524],{"trials":594,"activeCount":51},[],{"trials":596,"activeCount":51},[],{"intervention":324,"totalTrials":8,"cells":598},{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":611,"NA":613},{"trials":600,"activeCount":51},[],{"trials":602,"activeCount":51},[],{"trials":604,"activeCount":51},[],{"trials":606,"activeCount":51},[607],{"nctId":315,"briefTitle":316,"status":99,"phases":608,"completion":318,"start":319,"enrollment":320,"conditions":609,"interventions":610},[43],[18],[323,324],{"trials":612,"activeCount":51},[],{"trials":614,"activeCount":51},[],{"intervention":616,"totalTrials":8,"cells":617},"MOVICOL",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":624,"PHASE4":636,"NA":638},{"trials":619,"activeCount":51},[],{"trials":621,"activeCount":51},[],{"trials":623,"activeCount":51},[],{"trials":625,"activeCount":51},[626],{"nctId":627,"briefTitle":628,"status":99,"phases":629,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":633,"interventions":634},"NCT00796354","Constipation Associated With Irritable Bowel Syndrome (IBS-C)",[43],"2010-02","2008-11",210,[436],[616,635],"Sugar Pill",{"trials":637,"activeCount":51},[],{"trials":639,"activeCount":51},[],{"intervention":635,"totalTrials":8,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":654,"NA":656},{"trials":643,"activeCount":51},[],{"trials":645,"activeCount":51},[],{"trials":647,"activeCount":51},[],{"trials":649,"activeCount":51},[650],{"nctId":627,"briefTitle":628,"status":99,"phases":651,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":652,"interventions":653},[43],[436],[616,635],{"trials":655,"activeCount":51},[],{"trials":657,"activeCount":51},[],{"intervention":438,"totalTrials":8,"cells":659},{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":672,"NA":674},{"trials":661,"activeCount":51},[],{"trials":663,"activeCount":51},[],{"trials":665,"activeCount":51},[],{"trials":667,"activeCount":51},[668],{"nctId":431,"briefTitle":432,"status":99,"phases":669,"primaryCompletion":101,"completion":102,"start":434,"enrollment":118,"conditions":670,"interventions":671},[43],[436],[410,438],{"trials":673,"activeCount":51},[],{"trials":675,"activeCount":51},[],{"intervention":677,"totalTrials":8,"cells":678},"NER1006, Day Before-Only Dosing",{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":685,"PHASE4":697,"NA":699},{"trials":680,"activeCount":51},[],{"trials":682,"activeCount":51},[],{"trials":684,"activeCount":51},[],{"trials":686,"activeCount":51},[687],{"nctId":688,"briefTitle":689,"status":99,"phases":690,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":695},"NCT02273141","Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults.",[43],"2015-08","2014-11",515,[20,32,28],[677,696],"SP+MS, Day Before-Only Dosing",{"trials":698,"activeCount":51},[],{"trials":700,"activeCount":51},[],{"intervention":696,"totalTrials":8,"cells":702},{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":709,"PHASE4":715,"NA":717},{"trials":704,"activeCount":51},[],{"trials":706,"activeCount":51},[],{"trials":708,"activeCount":51},[],{"trials":710,"activeCount":51},[711],{"nctId":688,"briefTitle":689,"status":99,"phases":712,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":713,"interventions":714},[43],[20,32,28],[677,696],{"trials":716,"activeCount":51},[],{"trials":718,"activeCount":51},[],{"intervention":720,"totalTrials":8,"cells":721},"NER1006, 2-Day Split-Dosing",{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":726,"PHASE3":728,"PHASE4":740,"NA":742},{"trials":723,"activeCount":51},[],{"trials":725,"activeCount":51},[],{"trials":727,"activeCount":51},[],{"trials":729,"activeCount":51},[730],{"nctId":731,"briefTitle":732,"status":99,"phases":733,"primaryCompletion":691,"completion":691,"start":734,"enrollment":735,"conditions":736,"interventions":737},"NCT02273167","Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.",[43],"2014-10",849,[20,32,28],[720,738,739],"NER1006,1-Day Morning Split-Dosing","MOVIPREP, 2-Day Split-Dosing",{"trials":741,"activeCount":51},[],{"trials":743,"activeCount":51},[],{"intervention":738,"totalTrials":8,"cells":745},{"EARLY_PHASE1":746,"PHASE1":748,"PHASE2":750,"PHASE3":752,"PHASE4":758,"NA":760},{"trials":747,"activeCount":51},[],{"trials":749,"activeCount":51},[],{"trials":751,"activeCount":51},[],{"trials":753,"activeCount":51},[754],{"nctId":731,"briefTitle":732,"status":99,"phases":755,"primaryCompletion":691,"completion":691,"start":734,"enrollment":735,"conditions":756,"interventions":757},[43],[20,32,28],[720,738,739],{"trials":759,"activeCount":51},[],{"trials":761,"activeCount":51},[],{"intervention":739,"totalTrials":8,"cells":763},{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":770,"PHASE4":776,"NA":778},{"trials":765,"activeCount":51},[],{"trials":767,"activeCount":51},[],{"trials":769,"activeCount":51},[],{"trials":771,"activeCount":51},[772],{"nctId":731,"briefTitle":732,"status":99,"phases":773,"primaryCompletion":691,"completion":691,"start":734,"enrollment":735,"conditions":774,"interventions":775},[43],[20,32,28],[720,738,739],{"trials":777,"activeCount":51},[],{"trials":779,"activeCount":51},[],{"intervention":348,"totalTrials":11,"cells":781},{"EARLY_PHASE1":782,"PHASE1":784,"PHASE2":786,"PHASE3":796,"PHASE4":798,"NA":800},{"trials":783,"activeCount":51},[],{"trials":785,"activeCount":51},[],{"trials":787,"activeCount":51},[788,792],{"nctId":339,"briefTitle":340,"status":99,"phases":789,"completion":309,"start":342,"enrollment":343,"conditions":790,"interventions":791},[42],[345],[347,348],{"nctId":350,"briefTitle":340,"status":99,"phases":793,"completion":352,"start":342,"enrollment":343,"conditions":794,"interventions":795},[42],[30],[347,348],{"trials":797,"activeCount":51},[],{"trials":799,"activeCount":51},[],{"trials":801,"activeCount":51},[],{"intervention":292,"totalTrials":8,"cells":803},{"EARLY_PHASE1":804,"PHASE1":806,"PHASE2":808,"PHASE3":814,"PHASE4":816,"NA":818},{"trials":805,"activeCount":51},[],{"trials":807,"activeCount":51},[],{"trials":809,"activeCount":51},[810],{"nctId":284,"briefTitle":285,"status":99,"phases":811,"completion":287,"start":288,"enrollment":289,"conditions":812,"interventions":813},[42],[18],[275,292],{"trials":815,"activeCount":51},[],{"trials":817,"activeCount":51},[],{"trials":819,"activeCount":51},[],{"intervention":821,"totalTrials":8,"cells":822},"NRL0706",{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":827,"PHASE3":837,"PHASE4":839,"NA":841},{"trials":824,"activeCount":51},[],{"trials":826,"activeCount":51},[],{"trials":828,"activeCount":51},[829],{"nctId":830,"briefTitle":831,"status":99,"phases":832,"primaryCompletion":833,"completion":833,"start":233,"enrollment":834,"conditions":835,"interventions":836},"NCT01251237","Study to Assess the Tolerability, Safety and Efficacy of an Adapted Gut Cleansing Solution in Routine Colon Cleansing Prior to Colonoscopies",[42],"2010-07",120,[25],[821],{"trials":838,"activeCount":51},[],{"trials":840,"activeCount":51},[],{"trials":842,"activeCount":51},[],{"intervention":844,"totalTrials":8,"cells":845},"NRL994",{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":860,"PHASE4":862,"NA":864},{"trials":847,"activeCount":51},[],{"trials":849,"activeCount":51},[],{"trials":851,"activeCount":51},[852],{"nctId":853,"briefTitle":854,"status":99,"phases":855,"primaryCompletion":856,"completion":856,"start":297,"enrollment":857,"conditions":858,"interventions":859},"NCT06597903","A Monocentric Study to Investigate a New Low Dose Oral Gut Cleansing Solution",[42],"2002-03",36,[20],[844],{"trials":861,"activeCount":51},[],{"trials":863,"activeCount":51},[],{"trials":865,"activeCount":51},[],{"intervention":867,"totalTrials":8,"cells":868},"1R, 2S-methoxamine hydrochloride",{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":883,"PHASE4":885,"NA":887},{"trials":870,"activeCount":51},[],{"trials":872,"activeCount":51},[],{"trials":874,"activeCount":51},[875],{"nctId":876,"briefTitle":877,"status":99,"phases":878,"primaryCompletion":130,"completion":400,"start":540,"enrollment":879,"conditions":880,"interventions":882},"NCT01656720","A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period",[42],417,[881],"Faecal Incontinence",[867],{"trials":884,"activeCount":51},[],{"trials":886,"activeCount":51},[],{"trials":888,"activeCount":51},[],{"intervention":890,"totalTrials":16,"cells":891},"NRL001",{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":942,"PHASE3":944,"PHASE4":946,"NA":948},{"trials":893,"activeCount":51},[],{"trials":895,"activeCount":51},[896,903,911,919,926,935],{"nctId":897,"briefTitle":898,"status":99,"phases":899,"primaryCompletion":131,"completion":102,"start":900,"enrollment":9,"conditions":901,"interventions":902},"NCT01175941","Effect of 7 Days of Dosing With a 10 mg Rectal Suppository of NRL001in Patients With Faecal Incontinence",[41],"2010-08",[15],[890],{"nctId":904,"briefTitle":905,"status":99,"phases":906,"primaryCompletion":833,"completion":833,"start":907,"enrollment":908,"conditions":909,"interventions":910},"NCT01099683","Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of a Single Rectal Application of 10 mg NRL001 in Elderly Subjects",[41],"2010-04",26,[15],[890],{"nctId":912,"briefTitle":913,"status":99,"phases":914,"primaryCompletion":915,"completion":915,"start":233,"enrollment":916,"conditions":917,"interventions":918},"NCT01099670","Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of 7.5, 10, 12.5 or 15 mg NRL001 in a 2 g Suppository for 14 Days",[41],"2010-06",48,[15],[890],{"nctId":920,"briefTitle":921,"status":99,"phases":922,"primaryCompletion":215,"start":923,"enrollment":857,"conditions":924,"interventions":925},"NCT00857467","Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001.",[41],"2009-02",[15],[890,890],{"nctId":927,"briefTitle":928,"status":99,"phases":929,"primaryCompletion":930,"completion":140,"start":931,"enrollment":932,"conditions":933,"interventions":934},"NCT00893607","Effect of Single Doses of 10 mg NRL001 Applied as a Suppository to the Anal Canal or Rectum",[41],"2007-08","2007-04",24,[15],[890],{"nctId":936,"briefTitle":937,"status":99,"phases":938,"primaryCompletion":216,"start":923,"enrollment":916,"conditions":939,"interventions":941},"NCT00850590","Study of Escalating Doses of NRL001 Given in Slow-release Rectal Suppositories of Different Weights",[41],[940],"Incontinence",[890],{"trials":943,"activeCount":51},[],{"trials":945,"activeCount":51},[],{"trials":947,"activeCount":51},[],{"trials":949,"activeCount":51},[],{"intervention":951,"totalTrials":11,"cells":952},"Ulimorelin",{"EARLY_PHASE1":953,"PHASE1":955,"PHASE2":974,"PHASE3":976,"PHASE4":978,"NA":980},{"trials":954,"activeCount":51},[],{"trials":956,"activeCount":51},[957,967],{"nctId":958,"briefTitle":959,"status":99,"phases":960,"primaryCompletion":961,"completion":961,"start":962,"enrollment":9,"conditions":963,"interventions":965},"NCT01405612","Study to Examine the Effect of Ulimorelin on the Pharmacokinetics of Midazolam in Healthy Volunteers",[41],"2011-07","2011-06",[964],"Digestive System Disorders",[966,951],"Midazolam",{"nctId":968,"briefTitle":969,"status":99,"phases":970,"primaryCompletion":470,"completion":470,"start":962,"enrollment":971,"conditions":972,"interventions":973},"NCT01405599","Evaluation of the Pharmacokinetics of Ulimorelin in Subjects With Hepatic Impairment and Healthy Subjects",[41],32,[964],[951],{"trials":975,"activeCount":51},[],{"trials":977,"activeCount":51},[],{"trials":979,"activeCount":51},[],{"trials":981,"activeCount":51},[],{"intervention":983,"totalTrials":8,"cells":984},"NRL001 cream",{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":996,"PHASE3":998,"PHASE4":1000,"NA":1002},{"trials":986,"activeCount":51},[],{"trials":988,"activeCount":51},[989],{"nctId":990,"briefTitle":991,"status":99,"phases":992,"primaryCompletion":141,"completion":993,"start":931,"enrollment":200,"conditions":994,"interventions":995},"NCT01406925","Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers",[41],"2007-06",[15],[983],{"trials":997,"activeCount":51},[],{"trials":999,"activeCount":51},[],{"trials":1001,"activeCount":51},[],{"trials":1003,"activeCount":51},[],{"intervention":425,"totalTrials":8,"cells":1005},{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1014,"PHASE3":1016,"PHASE4":1018,"NA":1020},{"trials":1007,"activeCount":51},[],{"trials":1009,"activeCount":51},[1010],{"nctId":417,"briefTitle":418,"status":99,"phases":1011,"primaryCompletion":420,"start":421,"enrollment":422,"conditions":1012,"interventions":1013},[41],[30],[410,425],{"trials":1015,"activeCount":51},[],{"trials":1017,"activeCount":51},[],{"trials":1019,"activeCount":51},[],{"trials":1021,"activeCount":51},[],{"intervention":1023,"totalTrials":8,"cells":1024},"PLENVU powder for oral solution",{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1039,"PHASE3":1041,"PHASE4":1043,"NA":1045},{"trials":1026,"activeCount":51},[],{"trials":1028,"activeCount":51},[1029],{"nctId":1030,"briefTitle":1031,"status":99,"phases":1032,"primaryCompletion":1033,"completion":1033,"start":1034,"enrollment":1035,"conditions":1036,"interventions":1038},"NCT03437265","A Pharmacokinetic Study of PLENVU® in Healthy Subjects",[41],"2020-10-05","2020-09-03",19,[1037],"Pharmacokinetic",[1023],{"trials":1040,"activeCount":51},[],{"trials":1042,"activeCount":51},[],{"trials":1044,"activeCount":51},[],{"trials":1046,"activeCount":51},[],{"intervention":1048,"totalTrials":8,"cells":1049},"Fleet enema",{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1061,"PHASE3":1063,"PHASE4":1065,"NA":1067},{"trials":1051,"activeCount":51},[],{"trials":1053,"activeCount":51},[1054],{"nctId":1055,"briefTitle":1056,"status":99,"phases":1057,"primaryCompletion":1058,"completion":129,"start":117,"enrollment":343,"conditions":1059,"interventions":1060},"NCT01715272","A Clinical Investigation to Demonstrate the Performance of a New Enema (TF037) in Distal Bowel Cleansing Compared With Fleet Enema",[41],"2012-12",[18],[1048],{"trials":1062,"activeCount":51},[],{"trials":1064,"activeCount":51},[],{"trials":1066,"activeCount":51},[],{"trials":1068,"activeCount":51},[],{"intervention":966,"totalTrials":8,"cells":1070},{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1079,"PHASE3":1081,"PHASE4":1083,"NA":1085},{"trials":1072,"activeCount":51},[],{"trials":1074,"activeCount":51},[1075],{"nctId":958,"briefTitle":959,"status":99,"phases":1076,"primaryCompletion":961,"completion":961,"start":962,"enrollment":9,"conditions":1077,"interventions":1078},[41],[964],[966,951],{"trials":1080,"activeCount":51},[],{"trials":1082,"activeCount":51},[],{"trials":1084,"activeCount":51},[],{"trials":1086,"activeCount":51},[],{"intervention":1088,"totalTrials":8,"cells":1089},"Klean-Prep®",{"EARLY_PHASE1":1090,"PHASE1":1092,"PHASE2":1105,"PHASE3":1107,"PHASE4":1109,"NA":1111},{"trials":1091,"activeCount":51},[],{"trials":1093,"activeCount":51},[1094],{"nctId":1095,"briefTitle":1096,"status":99,"phases":1097,"primaryCompletion":208,"completion":1098,"start":1099,"enrollment":971,"conditions":1100,"interventions":1103},"NCT00896246","Scintigraphic Assessment Following Klean-Prep® or Moviprep®",[41],"2006-11","2006-09",[1101,1102],"Gastric Emptying","Healthy",[1088,1104],"Moviprep®",{"trials":1106,"activeCount":51},[],{"trials":1108,"activeCount":51},[],{"trials":1110,"activeCount":51},[],{"trials":1112,"activeCount":51},[],{"intervention":1104,"totalTrials":8,"cells":1114},{"EARLY_PHASE1":1115,"PHASE1":1117,"PHASE2":1123,"PHASE3":1125,"PHASE4":1127,"NA":1129},{"trials":1116,"activeCount":51},[],{"trials":1118,"activeCount":51},[1119],{"nctId":1095,"briefTitle":1096,"status":99,"phases":1120,"primaryCompletion":208,"completion":1098,"start":1099,"enrollment":971,"conditions":1121,"interventions":1122},[41],[1101,1102],[1088,1104],{"trials":1124,"activeCount":51},[],{"trials":1126,"activeCount":51},[],{"trials":1128,"activeCount":51},[],{"trials":1130,"activeCount":51},[],{"intervention":1132,"totalTrials":8,"cells":1133},"Perianal NRL001 Gel 3 strengths",{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1150,"PHASE3":1152,"PHASE4":1154,"NA":1156},{"trials":1135,"activeCount":51},[],{"trials":1137,"activeCount":51},[1138],{"nctId":1139,"briefTitle":1140,"status":99,"phases":1141,"primaryCompletion":1142,"completion":1143,"start":318,"enrollment":1144,"conditions":1145,"interventions":1146},"NCT06593743","The Safety and Dose Response to Single Anal Doses of NRL001",[41],"2004-07","2013-11-12",44,[881],[1132,1147,1148,1149],"Intraanal NRL001 Gel 2 strengths","Intrarectal NRL001 Gel","NRL001: 10mg suppository",{"trials":1151,"activeCount":51},[],{"trials":1153,"activeCount":51},[],{"trials":1155,"activeCount":51},[],{"trials":1157,"activeCount":51},[],{"intervention":1147,"totalTrials":8,"cells":1159},{"EARLY_PHASE1":1160,"PHASE1":1162,"PHASE2":1168,"PHASE3":1170,"PHASE4":1172,"NA":1174},{"trials":1161,"activeCount":51},[],{"trials":1163,"activeCount":51},[1164],{"nctId":1139,"briefTitle":1140,"status":99,"phases":1165,"primaryCompletion":1142,"completion":1143,"start":318,"enrollment":1144,"conditions":1166,"interventions":1167},[41],[881],[1132,1147,1148,1149],{"trials":1169,"activeCount":51},[],{"trials":1171,"activeCount":51},[],{"trials":1173,"activeCount":51},[],{"trials":1175,"activeCount":51},[],{"intervention":1148,"totalTrials":8,"cells":1177},{"EARLY_PHASE1":1178,"PHASE1":1180,"PHASE2":1186,"PHASE3":1188,"PHASE4":1190,"NA":1192},{"trials":1179,"activeCount":51},[],{"trials":1181,"activeCount":51},[1182],{"nctId":1139,"briefTitle":1140,"status":99,"phases":1183,"primaryCompletion":1142,"completion":1143,"start":318,"enrollment":1144,"conditions":1184,"interventions":1185},[41],[881],[1132,1147,1148,1149],{"trials":1187,"activeCount":51},[],{"trials":1189,"activeCount":51},[],{"trials":1191,"activeCount":51},[],{"trials":1193,"activeCount":51},[],{"intervention":1149,"totalTrials":8,"cells":1195},{"EARLY_PHASE1":1196,"PHASE1":1198,"PHASE2":1204,"PHASE3":1206,"PHASE4":1208,"NA":1210},{"trials":1197,"activeCount":51},[],{"trials":1199,"activeCount":51},[1200],{"nctId":1139,"briefTitle":1140,"status":99,"phases":1201,"primaryCompletion":1142,"completion":1143,"start":318,"enrollment":1144,"conditions":1202,"interventions":1203},[41],[881],[1132,1147,1148,1149],{"trials":1205,"activeCount":51},[],{"trials":1207,"activeCount":51},[],{"trials":1209,"activeCount":51},[],{"trials":1211,"activeCount":51},[],{"intervention":1213,"totalTrials":8,"cells":1214},"NRL001 cream 0.5%w\u002Fw",{"EARLY_PHASE1":1215,"PHASE1":1217,"PHASE2":1231,"PHASE3":1233,"PHASE4":1235,"NA":1237},{"trials":1216,"activeCount":51},[],{"trials":1218,"activeCount":51},[1219],{"nctId":1220,"briefTitle":1221,"status":99,"phases":1222,"primaryCompletion":930,"completion":1223,"start":930,"enrollment":224,"conditions":1224,"interventions":1225},"NCT06593730","Safety and Tolerability of the Twice Daily Intra-anal Application of NRL001 Cream for 14 Days",[41],"2007-09",[881],[1213,1226,1227,1228,1229,1230],"NRL001 cream 0.75%w\u002Fw","NRL001 cream 1.0%w\u002Fw","NRL001 cream 1.5%w\u002Fw","NRL001 cream 2.0%w\u002Fw","NRL001 cream 2.5%w\u002Fw",{"trials":1232,"activeCount":51},[],{"trials":1234,"activeCount":51},[],{"trials":1236,"activeCount":51},[],{"trials":1238,"activeCount":51},[],{"intervention":1226,"totalTrials":8,"cells":1240},{"EARLY_PHASE1":1241,"PHASE1":1243,"PHASE2":1249,"PHASE3":1251,"PHASE4":1253,"NA":1255},{"trials":1242,"activeCount":51},[],{"trials":1244,"activeCount":51},[1245],{"nctId":1220,"briefTitle":1221,"status":99,"phases":1246,"primaryCompletion":930,"completion":1223,"start":930,"enrollment":224,"conditions":1247,"interventions":1248},[41],[881],[1213,1226,1227,1228,1229,1230],{"trials":1250,"activeCount":51},[],{"trials":1252,"activeCount":51},[],{"trials":1254,"activeCount":51},[],{"trials":1256,"activeCount":51},[],{"intervention":1227,"totalTrials":8,"cells":1258},{"EARLY_PHASE1":1259,"PHASE1":1261,"PHASE2":1267,"PHASE3":1269,"PHASE4":1271,"NA":1273},{"trials":1260,"activeCount":51},[],{"trials":1262,"activeCount":51},[1263],{"nctId":1220,"briefTitle":1221,"status":99,"phases":1264,"primaryCompletion":930,"completion":1223,"start":930,"enrollment":224,"conditions":1265,"interventions":1266},[41],[881],[1213,1226,1227,1228,1229,1230],{"trials":1268,"activeCount":51},[],{"trials":1270,"activeCount":51},[],{"trials":1272,"activeCount":51},[],{"trials":1274,"activeCount":51},[],{"intervention":1228,"totalTrials":8,"cells":1276},{"EARLY_PHASE1":1277,"PHASE1":1279,"PHASE2":1285,"PHASE3":1287,"PHASE4":1289,"NA":1291},{"trials":1278,"activeCount":51},[],{"trials":1280,"activeCount":51},[1281],{"nctId":1220,"briefTitle":1221,"status":99,"phases":1282,"primaryCompletion":930,"completion":1223,"start":930,"enrollment":224,"conditions":1283,"interventions":1284},[41],[881],[1213,1226,1227,1228,1229,1230],{"trials":1286,"activeCount":51},[],{"trials":1288,"activeCount":51},[],{"trials":1290,"activeCount":51},[],{"trials":1292,"activeCount":51},[],{"intervention":1229,"totalTrials":8,"cells":1294},{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1303,"PHASE3":1305,"PHASE4":1307,"NA":1309},{"trials":1296,"activeCount":51},[],{"trials":1298,"activeCount":51},[1299],{"nctId":1220,"briefTitle":1221,"status":99,"phases":1300,"primaryCompletion":930,"completion":1223,"start":930,"enrollment":224,"conditions":1301,"interventions":1302},[41],[881],[1213,1226,1227,1228,1229,1230],{"trials":1304,"activeCount":51},[],{"trials":1306,"activeCount":51},[],{"trials":1308,"activeCount":51},[],{"trials":1310,"activeCount":51},[],{"intervention":1230,"totalTrials":8,"cells":1312},{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1321,"PHASE3":1323,"PHASE4":1325,"NA":1327},{"trials":1314,"activeCount":51},[],{"trials":1316,"activeCount":51},[1317],{"nctId":1220,"briefTitle":1221,"status":99,"phases":1318,"primaryCompletion":930,"completion":1223,"start":930,"enrollment":224,"conditions":1319,"interventions":1320},[41],[881],[1213,1226,1227,1228,1229,1230],{"trials":1322,"activeCount":51},[],{"trials":1324,"activeCount":51},[],{"trials":1326,"activeCount":51},[],{"trials":1328,"activeCount":51},[],{"intervention":1330,"totalTrials":8,"cells":1331},"1L PEG + ASCORBIC ACID",{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1338,"PHASE4":1340,"NA":1342},{"trials":1333,"activeCount":51},[],{"trials":1335,"activeCount":51},[],{"trials":1337,"activeCount":51},[],{"trials":1339,"activeCount":51},[],{"trials":1341,"activeCount":51},[],{"trials":1343,"activeCount":51},[1344],{"nctId":1345,"briefTitle":1346,"status":99,"phases":1347,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1350,"conditions":1351,"interventions":1353},"NCT05174845","Real Word Evidence With 1L Polyethylene Glycol (PEG)+ Ascorbic Acid in Iberia",[],"2022-03-01","2021-10-01",13393,[25,1352,28],"Colon Disease",[1330],{"intervention":1355,"totalTrials":8,"cells":1356},"Fleet",{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1361,"PHASE3":1363,"PHASE4":1365,"NA":1367},{"trials":1358,"activeCount":51},[],{"trials":1360,"activeCount":51},[],{"trials":1362,"activeCount":51},[],{"trials":1364,"activeCount":51},[],{"trials":1366,"activeCount":51},[],{"trials":1368,"activeCount":51},[1369],{"nctId":1370,"briefTitle":1371,"status":99,"phases":1372,"primaryCompletion":541,"completion":1058,"start":131,"enrollment":1373,"conditions":1374,"interventions":1375},"NCT02468726","Performance of NER1008 Enema Compared With Fleet® Enema in Bowel Cleansing",[45],25,[20],[1355]]